Literature DB >> 26622881

Effect of temozolomide on the viability of musculoskeletal sarcoma cells.

Yuta Kusabe1, Hiroyuki Kawashima2, Akira Ogose2, Taro Sasaki2, Takashi Ariizumi3, Tetsuo Hotta2, Naoto Endo2.   

Abstract

Musculoskeletal sarcomas (MSS) are a heterogeneous group of malignancies with relatively high mortality rates. The prognosis for patients with MSS is poor, with few drugs inducing measurable activity. Alkylating agents, namely ifosfamide and dacarbazine, which act nonspecifically on proliferating cells, are the typical therapy prescribed for advanced MSS. A novel alkylating agent, temozolomide (TMZ), has several advantages over existing alkylating agents. TMZ induces the formation of O6-methylguanine in DNA, thereby inducing mismatches during DNA replication and the subsequent activation of apoptotic pathways. However, due to conflicting data in the literature, the mechanism of TMZ action has remained elusive. Therefore, the present study aimed to evaluate apoptosis in MSS cells treated with TMZ, and to evaluate the correlation between TMZ action and survival pathways, including the phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK)1/2 mitogen activated protein kinase (MAPK) pathways. Cell proliferation was evaluated by performing an XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) assay. Apoptotic morphological changes, for example chromatin condensation, were evaluated by fluorescence confocal microscopy. The expression of the apoptosis-associated proteins caspase-3, poly adenosine diphosphate ribose polymerase (PARP), Akt and ERK1/2, was determined by western blotting. The results of the present study indicated that, in certain MSS cells, the IC50 value was lower than that in TMZ-sensitive U-87 MG cells. Furthermore, TMZ treatment was associated with apoptotic morphological changes and the expression levels of pro-apoptotic cleaved caspase-3 and PARP were also increased in TMZ-treated MSS cells. In addition, the results indicated that PI3K/Akt and ERK1/2 MAPK were constitutively phosphorylated in MSS cells, and phosphorylation of PI3K/Akt was suppressed in certain cells, and maintained in other cells, by TMZ. These observations emphasized the plasticity of MSS cells, and suggested that this plasticity may contribute to the variance in cell sensitivity to TMZ and TMZ-resistance in MSS.

Entities:  

Keywords:  apoptosis; musculoskeletal sarcoma; phosphoinositide 3-kinase/Akt; temozolomide

Year:  2015        PMID: 26622881      PMCID: PMC4580084          DOI: 10.3892/ol.2015.3506

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

2.  A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Authors:  Xavier Garcia del Muro; Antonio Lopez-Pousa; Javier Martin; Jose M Buesa; Javier Martinez-Trufero; Antonio Casado; Andres Poveda; Josefina Cruz; Isabel Bover; Joan Maurel
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

3.  Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.

Authors:  J A Gottlieb; R S Benjamin; L H Baker; R M O'Bryan; J G Sinkovics; B Hoogstraten; J M Quagliana; S E Rivkin; G P Bodey; V Rodriguez; G R Blumenschein; J H Saiki; C Coltman; M A Burgess; P Sullivan; T Thigpen; R Bottomley; S Balcerzak; T E Moon
Journal:  Cancer Treat Rep       Date:  1976-02

4.  Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.

Authors:  Maria De Salvo; Giovanna Maresca; Igea D'agnano; Rodolfo Marchese; Antonio Stigliano; Raffaella Gagliassi; Ercole Brunetti; Giorgio H Raza; Ugo De Paula; Barbara Bucci
Journal:  Int J Radiat Biol       Date:  2011-03-15       Impact factor: 2.694

5.  Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.

Authors:  Haiyan Wang; Shanbao Cai; Aaron Ernstberger; Barbara J Bailey; Michael Z Wang; Wenjing Cai; W Scott Goebel; Magdalena B Czader; Colin Crean; Attaya Suvannasankha; Inna Shokolenkoc; Glenn L Wilson; Arthur R Baluyut; Lindsey D Mayo; Karen E Pollok
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

6.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.

Authors:  T Kanzawa; I M Germano; T Komata; H Ito; Y Kondo; S Kondo
Journal:  Cell Death Differ       Date:  2004-04       Impact factor: 15.828

7.  Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).

Authors:  P Aman; D Ron; N Mandahl; T Fioretos; S Heim; K Arheden; H Willén; A Rydholm; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

8.  Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1.

Authors:  Akira Kawai; Noriko Naito; Aki Yoshida; Yuki Morimoto; Mamoru Ouchida; Kenji Shimizu; Yasuo Beppu
Journal:  Cancer Lett       Date:  2004-02-10       Impact factor: 8.679

9.  O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.

Authors:  Jens Jakob; Maren Hille; Christian Sauer; Philipp Ströbel; Frederik Wenz; Peter Hohenberger
Journal:  Radiat Oncol       Date:  2012-10-30       Impact factor: 3.481

10.  Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.

Authors:  Lei Wu; Liang Yang; Yu Xiong; Hua Guo; Xiaoli Shen; Zujue Cheng; Yan Zhang; Ziyun Gao; Xingen Zhu
Journal:  Tumour Biol       Date:  2014-09-23
View more
  2 in total

1.  Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Authors:  Laura Ferrer-Font; Lucia Villamañan; Nuria Arias-Ramos; Jordi Vilardell; Maria Plana; Maria Ruzzene; Lorenzo A Pinna; Emilio Itarte; Carles Arús; Ana Paula Candiota
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-12

2.  Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.

Authors:  Manojkumar Bupathi; John L Hays; James L Chen
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.